

Haematologica
HAEMATOL/2019/240739
Version 3

Why is it critical to achieve a deep molecular response in chronic
myeloid leukemia?

Susan Branford

Disclosures: Member of the advisory board of Qiagen, Novartis and Bristol-Myers Squibb and consultant for Cepheid. Received honoraria from Qiagen, Novartis, Bristol-Myers Squibb and Cepheid. Research support from Novartis.